Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

Prostamax

Urinary comfort and prostate support. Prostamax is discussed for prostate-related urinary symptoms, including weak flow, frequent urination and pelvic discomfort.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Molecular formula
C₂₀H₃₃N₅O₉
Average mass
487.5 Da
CAS number
473578-47-1
Registry
PubChem CID 9848296
Formula, mass and identifiers from PubChem CID 9848296.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Prostamax (KEDP) is a synthetic peptide bioregulator engineered specifically to restore prostate tissue health and support male urinary function.

What problem it targets: It targets benign prostatic hyperplasia (BPH), frequent nighttime urination, weak urinary stream, chronic non-bacterial prostatitis, and male pelvic discomfort.

What It Does

• Normalizes prostate cellular metabolism: Enters prostate cells to stimulate proper protein synthesis, reducing abnormal tissue hypertrophy and cellular swelling.

• Relieves urinary frequency and hesitation: By calming localized prostate inflammation, it alleviates physical compression on the urethra, restoring normal urinary flow.

• Enhances male pelvic microcirculation: Improves capillary blood perfusion and fluid drainage throughout the prostate gland, preventing congested inflammation.

• Realistic expectations: Cycled in 10- to 20-day courses. Men typically notice a reduction in nighttime bathroom trips and improved urinary flow within 2 to 3 weeks.

Reconstitution

Vial SizeBAC Water / SolventConcentration
20 mg (assumed vial strength)2 mL bacteriostatic water (requested mixing example)10 mg/mL = 10,000 micrograms/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Presentation

20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.

Protocol

Community protocols & cycle timing

PhaseFrequencyAmountNotes
Common community cycle pattern10–20 consecutive days; a few courses per year with months between coursesCompound- and formulation-specific; see rows belowA shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses.
Community-reported courseDaily, subcutaneous; 20 days at time of report1 mg per compoundCombined Testagen/Prostamax report; commenter had not noticed a difference at that point. Do not attribute outcomes to either compound alone. This is an anecdote, not a recommended regimen.

Research study amounts

PhaseFrequencyAmountNotes
Rat prostate tissue cultureOrgan-culture experiment0.05 ng/mL2006 study. Growth in tissue cultures, not a clinical urinary-symptom endpoint.

About these protocols

The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.

Handling & Stacking

Organ / tissue
Prostate gland
Cycle pattern
  • Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
  • This describes a community cycle pattern, not one universal dose.
  • Some finished oral products instead specify a 30-day course or 10-day maintenance course.
Injection site / route
  • Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
  • This does not establish an approved administration route for this compound.
Storage
  • No compound-specific universal storage temperature or post-mixing stability period was verified.
  • Use the supplier’s stability data for that formulation.
  • Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
Side effects
Injection-site irritation is possible with injectable preparations. Compound-specific human adverse-event rates are not established.
What to expect
Users seek better urinary flow and less disruption from urinary symptoms. Community reports mix formulations and do not establish a predictable response.
Pairs discussed
Testagen is reported alongside Prostamax in community courses. These are reported pairings, not demonstrated synergy.
Avoid / interactions
Persistent urinary symptoms, blood in urine or inability to urinate should not be treated as a routine peptide experiment.
Approved treatment context
  • The named preparation is not established here as an approved treatment for its marketed goals.
  • Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.

Safety & Patient Education

What remains uncertain
Effects on prostate enlargement, PSA interpretation and prostate-cancer outcomes are not established by these studies.
Evidence boundary
The reviewed studies do not establish a standard human dose, frequency, course length or long-term adverse-event rate.
Identity check
Prostamax, Prostatilen and Libidon are separate products. Evidence for a prostate extract should not be relabelled as evidence for KEDP.